Hong Kong’s AI drug discovery firm Insilico closes $60M Series D

Insilico Medicine, a Hong Kong-based company that has been using artificial intelligence to discover new drugs since 2014, has completed a fresh round of funding. It’s a sign that certain investors are continuing to bet on emerging biotechnologies — which often take longer to prove profitability compared to other verticals — at a time venture […]

This content has been restricted to logged in users only. Please login to view this content.